Skip to main content
SpringerLink
Log in

Motor Neuron Disease

  • Chapter
Book cover Controlled Clinical Trials in Neurological Disease

Part of the book series: Foundations of Neurology ((FONY,volume 1))

Abstract

For over a century, the clinical and pathological essentials of motor neuron degeneration have been described [1]. Yet to this date, no cogent, easily applied quantiative description of the course of motor neuron degeneration has been forthcoming [2]. A complete understanding of the clinical features of motor neuron disease, both in the individual and within a group of affected individuals, is necessary for the optimal conduct of therapeutic trials. Precise endpoints are required to permit statistical planning of clinical trials, which will include determination of sample size, trial duration, and mode of analysis. In this chapter we will review the strategies to be applied when determining the best measures of change in individual patients or groups of patients with motor neuron disease over different time periods. We will also analyze the different statistical needs of individual case studies and parallel placebo-controlled case studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Caroscio JT, Mulvihill MN, Sterling R, et al. (1987). Amyotrophic lateral sclerosis: Its natural history. Neurol Clin 5:1–8.

    PubMed  CAS  Google Scholar 

  2. Andres PL, Skerry LM, Munsat TL (1989). Measurement of strength in neuromuscular diseases. In Munsat TL (ed.), Quantification of Neurologic Deficit. Boston: Butterworths, pp. 87–100.

    Google Scholar 

  3. Zack MM, Levitt LP, Schoenberg B. (1982). Motor neuron disease in Lehigh county, Pennsylvania: An epidemiologic study. J. Chron Dis 30:813–818.

    Article  Google Scholar 

  4. Brooks BR (1989). A summary of the current position of TRH in ALS therapy. Ann NY Acad Sci 553:431–461.

    Article  PubMed  CAS  Google Scholar 

  5. Brooks BR, Sufit RL, Montgomery GK, et al. (1987). Intravenous thyrotropin releasing hormone in patients with amyotrophic lateral sclerosis: Dose-response and randomized concurrent placebo-controlled pilot studies. Neurol Clin 5:143–158.

    PubMed  CAS  Google Scholar 

  6. Beaulieu DA, Erickson LM, Williams A, et al. (1987). Intravenous thyrotropin releasing hormone in amyotrophic lateral sclerosis: Autonomic effects. Neurol Clin 5:269–290.

    PubMed  CAS  Google Scholar 

  7. DePaul R, Abbs JH (1987). Manifestations of ALS in the cranial motor nerves — Dynametric, neuropathologic and speech motor data. Neurol Clin 5:231–250.

    PubMed  CAS  Google Scholar 

  8. Robbins JA (1987). Swallowing in ALS and motor neuron disorders. Neurol Clin 5:213–229.

    PubMed  CAS  Google Scholar 

  9. Brooks BR (1985). Test protocol development: Further preliminary experience with the effects of TRH in ALS. Muscle Nerve 8:460–465.

    Google Scholar 

  10. Brooks BR, Beaulieu D, Erickson L, et al. (1986). Pilot studies and clinical therapeutic trials in amyotrophic lateral sclerosis. Muscle Nerve 9(Suppl S5):90.

    Google Scholar 

  11. Appel V, Stewart SS, Smith G, et al. (1987). A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 22:328–333.

    Article  PubMed  CAS  Google Scholar 

  12. Appel SH, Stewart SS, Appel V, et al. (1988). A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45:381–386.

    PubMed  CAS  Google Scholar 

  13. Brooks BR, Beaulieu D, Biletch M, et al. (1988). Chronic subcutaneous administration of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Ann Neurol 24:164A.

    Google Scholar 

  14. Medical Research Council (1943). Aids to the investigation of peripheral nerve injuries. War Memorandum, Edition 2(revised). London: HSMO, pp. 11–46.

    Google Scholar 

  15. John J (1984). Grading of muscle power: Comparison of MRC and analogue scales by physiotherapists. Int J Rehab Res 7:173–181.

    Article  CAS  Google Scholar 

  16. Norris FH, Calanchini PR, Fallat RJ, et al. (1974). The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24:721–728.

    PubMed  Google Scholar 

  17. Andres PL, Hedlund W, Finison L, et al. (1986). Quantitative motor assessment in amyotrophic lateral sclerosis: Neurology 36:937–941.

    PubMed  CAS  Google Scholar 

  18. Andres PL, Finison LJ, Conlon T, et al. (1988). Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 38:405–408.

    PubMed  CAS  Google Scholar 

  19. Munsat TL, Andres PL, Finison L, et al. (1988). The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 38:409–413.

    PubMed  CAS  Google Scholar 

  20. Sharrard WJW (1955). The distribution of permanent paralysis in the lower limb in poliomyelitis. J Bone Joint Surg 37B:540–558.

    Google Scholar 

  21. Tan Y-D, Dolan P, Brooks BR (1988). Symptom progression in amyotrophic lateral sclerosis. Ann Neurol 24:149A.

    Google Scholar 

  22. Jackson AC, Moench TR, Griffin DE, et al. (1987). The pathogenesis of spinal cord involvement in the encephalomyelitis of mice caused by neuroadapted Sindbis virus infection. Lab Invest 56:418–423.

    PubMed  CAS  Google Scholar 

  23. Caroscio JT, Cohen JA, Zawodniak J, et al. (1986). A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 36:141–145.

    PubMed  CAS  Google Scholar 

  24. Plaitakis A, Smith J, Mandeli J, et al. (1988). Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet 1:1015–1018.

    Article  PubMed  CAS  Google Scholar 

  25. Brooke MH, Florence JM, Heller SL, et al. (1986). Controlled trial of thyrotropin releasing hormone in amyotrophic latearl sclerosis. Neurology 36:146–151.

    PubMed  CAS  Google Scholar 

  26. Kuther G, Struppler A, Lipinski HG (1987). Therapeutic trials in ALS — The design of a protocol. In Cosi V, Kato AC, Parlette W, Pinelli P, Poloni M (eds.), Amyotrophic Lateral Sclerosis: Therapeutic, Psychological and Research Aspects. Adv Exp Med Biol 209:265–276.

    Google Scholar 

  27. Kuther G, Struppler A (1987). Therapeutic trial with N-acetylcysteine in amyotrophic lateral sclerosis. In Cosi V, Kato AC, Parlette W, Pinelli P, Poloni M (eds.), Amyotrophic Lateral Sclerosis: Therapeutic, Psychological and Research Aspects. Adv Exp Med Biol 209:281–284.

    Google Scholar 

  28. Brooks BR, Sufit RL, Clough JA, et al. (1989). Isokinetic and functional evaluation of muscle strength over time in amyotrophic lateral sclerosis. In Munsat TL (ed.), Quantification of Neurologic Deficit. Boston: Butterworths, pp. 143–154.

    Google Scholar 

  29. Sufit RL, CloughJA, Schramm M, et al. (1987). Isokinetic assessment in ALS. Neurol Clin 5:197–212.

    PubMed  CAS  Google Scholar 

  30. Olarte MR, Gersten JC, ZabriskieJ, et al. (1978). Transfer factor is ineffective in amyotrophic lateral sclerosis. Ann Neurol 5:385–388.

    Article  Google Scholar 

  31. Olarte MR (1982). Therapeutic trials in amyotrophic lateral sclerosis. In Rowland LP (ed.), Human Motor Neuron Diseases. New York Raven Press, pp. 555–557.

    Google Scholar 

  32. Shafer SQ, Olarte MR (1982). Methodological considerations for clinical trials in motor neuron disease. In Rowland LP (ed.), Human Motor Neuron Diseases. New York: Raven Press, pp. 559–568.

    Google Scholar 

  33. Sanjak M, Paulson D, Sufit R, et al. (1987). Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis. Neurology 37:1217–1220.

    PubMed  CAS  Google Scholar 

  34. Braun SR (1987). Respiratory system in amyotrophic lateral sclerosis. Neurol Clin 5:9–31.

    PubMed  CAS  Google Scholar 

  35. Miller JP (1989). Statistical considerations for quantitative techniques in clinical neurology. In Munsat TL (ed.), Quantification of Neurology Deficit. Boston: Butterworths, pp. 69–84.

    Google Scholar 

  36. Andres PL, Skerry LM, Munsat TL (1989). Measurement of strength in neuromuscular diseases. In Munsat TL (ed.), Quantification of Neurologic Deficit. Boston: Butterworths, pp. 87–100.

    Google Scholar 

  37. Munsat TL, Andres PL, Skerry LM (1989). The use of quantitative techniques to define amyotrophic lateral sclerosis. In Munsat TL (ed.), Quantification of Neurologic Deficit. Boston: Butterworths, pp. 129–142.

    Google Scholar 

  38. Dworkin JP (1980). Tongue strength measurement in patients with amyotrophic lateral sclerosis: Qualitative vs. quantitative procedures. Arch Phys Med Rehabil 61:422–424.

    PubMed  CAS  Google Scholar 

  39. Dworkin JP, Aronson AE (1986). Tongue strength and alternate motion rates in normal and dysarthric subjects. J Commun Disord 19:115–132.

    Article  PubMed  CAS  Google Scholar 

  40. Edwards RHT, Young A, Hosking GP, et al. (1977). Human skeletal muscle function: Description of tests and normal values. Clin Sci Mol Med 52:283–290.

    PubMed  CAS  Google Scholar 

  41. Shaunak S, Ang L, Colston K, et al. (1987). Muscle strength in healthy white and asian subjects: The relationship of quadriceps maximum voluntary contraction to age, sex, body build and vitamin D. Clin Sci 73:541–546.

    PubMed  CAS  Google Scholar 

  42. De Boer A, Boukes RJ, SterkJC (1982). Reliability of dynamometry in patients with a neuromuscular disorder. Eng Med 11:169–174.

    Article  PubMed  Google Scholar 

  43. Festoff B, Smith RA, Melmud S, et al. (1988). Tufts quantitative neuromuscular examination and amyotrophic lateral sclerosis in the recombinant age. Ann Neurol 24:138A-139A.

    Google Scholar 

  44. Agre JC, Magness JS, Hull SZ, et al. (1987). Strength testing with a portable dynamometer: Reliability for upper and lower extremities. Arch Phys Med Rehabil 68:454–458.

    PubMed  CAS  Google Scholar 

  45. Patterson RP, Baxter T (1988). A multiple muscle strength testing protocol. Arch Phys Med Rehabil 69:366–368.

    PubMed  CAS  Google Scholar 

  46. Eidelberg E, Miller AL, Schwartzman RJ, et al. (1987). Measurements of regional glucose metabolism in studies of motor control. J Neurosci Methods 21:139–144.

    Article  PubMed  CAS  Google Scholar 

  47. Homma S, Sako H, Kohno K, et al. (1988). The pattern of distribution of serotoninergic fibers in the anterior horn of the chick spinal cord. Anat Embryol (Bed) 179:25–31.

    Article  CAS  Google Scholar 

  48. Hori Y, Endo K, Willis WD (1986). Synaptic actions of cutaneous A delta and C fibers on primate hindlimb alpha-motoneurons. Neurosci Res 3:411–429.

    Article  PubMed  CAS  Google Scholar 

  49. Fung SJ, Pompeiano O, Barnes CD (1988). Coerulospinal influence on recurrent inhibition of spinal motonuclei innervating antagonistic hind leg muscles of the cat. Pflugers Arch 412: 346–353.

    Article  PubMed  CAS  Google Scholar 

  50. Bohannon RW (1986). Test-retest reliability of hand-held dynamometry during a single session of strength assessment. Phys Ther 66:206–209.

    PubMed  CAS  Google Scholar 

  51. Gubbay SS, Kahana E, Zilber N, et al. (1985). Amyotrophic lateral sclerosis: A study of its presentation and prognosis. J Neurol 232:295–300.

    Article  PubMed  CAS  Google Scholar 

  52. Carpenter RJ, McDonald TJ, Howard FM (1978). The otolaryngologic presentation of amyotrophic lateral sclerosis. Otolaryngology 86:479–484.

    Google Scholar 

  53. Carrow E, Rivers V, Mauldin M, et al. (1974). Deviant speech characteristics in motor neuron disease. Arch Otolaryngol 100:212–218.

    PubMed  CAS  Google Scholar 

  54. DePaul R, Abbs JH, Caligiuri M, et al. (1988). Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis. Neurology 38:281–283.

    PubMed  CAS  Google Scholar 

  55. Caruso AJ, Burton EK (1987). Temporal acoustic measures of dysarthria associated with amyotrophic lateral sclerosis. J Speech Hearing Res 30:80–87.

    PubMed  CAS  Google Scholar 

  56. Dworkin JP, Aronson AE, Mulder DW (1980). Tongue forces in normals and in dysarthric patients with amyotrophic lateral sclerosis. J Speech Hearing Res 23:828–837.

    PubMed  CAS  Google Scholar 

  57. Kent RD, Kent JF, Weismer G, et al. (1989). Relationship between speech intelligibility and the slope of second-Formant transitions in dysarthric subjects. Clin Linguistics Phonetics 3:347–358.

    Article  Google Scholar 

  58. Kalbfleisch JD, Prentice RI (1980). The Statistical Analysis of Failure Time Data. New York: Wiley, pp. 1–320.

    Google Scholar 

  59. Fleiss JL, Tytun A, Ury HK (1988). A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 36:343–346.

    Article  Google Scholar 

  60. Schoenberg BS (1982). Controlled therapeutic trials in motor neuron disease: methodologic considerations. In Rowland LP (ed.), Human Motor Neuron Diseases. New York: Raven Press, pp. 547–553.

    Google Scholar 

Download references

Authors
  1. Benjamin Rix Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roxanne Depaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan De Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammed Sanjak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert L. Sufit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joanne Robbins
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

    Roger J. Porter  & Bruce S. Schoenberg  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Kluwer Academic Publishers

About this chapter

Cite this chapter

Brooks, B.R., Depaul, R., De Tan, Y., Sanjak, M., Sufit, R.L., Robbins, J. (1990). Motor Neuron Disease. In: Porter, R.J., Schoenberg, B.S. (eds) Controlled Clinical Trials in Neurological Disease. Foundations of Neurology, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1495-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1495-0_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8804-6

  • Online ISBN: 978-1-4613-1495-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation